海特生物跌2.02%，成交额2.00亿元，主力资金净流入1050.28万元

Company Overview - Hite Bio is located in Wuhan Economic and Technological Development Zone, established on April 8, 1992, and listed on August 8, 2017. The company focuses on the research, production, and sales of innovative biopharmaceuticals, as well as providing small molecule chemical pharmaceutical research and contract drug manufacturing services [1][2]. Financial Performance - For the first half of 2025, Hite Bio reported revenue of 275 million yuan, a year-on-year decrease of 3.36%. The net profit attributable to the parent company was -39.18 million yuan, reflecting a significant year-on-year decline of 72.10% [2]. - The company has distributed a total of 85.23 million yuan in dividends since its A-share listing, with 17.02 million yuan distributed over the past three years [3]. Stock Performance - As of September 9, Hite Bio's stock price was 40.83 yuan per share, with a market capitalization of 5.344 billion yuan. The stock has increased by 72.21% year-to-date but has seen a decline of 9.31% over the last five trading days and 19.12% over the last 20 days [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent appearance on July 23 [1]. Shareholder Information - As of August 29, Hite Bio had 14,600 shareholders, an increase of 8.86% from the previous period. The average number of tradable shares per shareholder was 8,349, which decreased by 8.14% [2]. Business Segments - The main revenue sources for Hite Bio include technical service income (57.20%), injectable mouse nerve growth factor (25.59%), and injectable Epoetin (17.04%), with other income contributing 0.17% [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing, and is involved in various concept sectors such as traditional Chinese medicine, raw materials, small-cap stocks, mergers and acquisitions, and the Hubei Free Trade Zone [2].